These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23306147)

  • 1. Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.
    Boada M; Arranz FJ
    Dement Geriatr Cogn Disord; 2013; 35(1-2):23-33. PubMed ID: 23306147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
    Gauthier S; Robillard A; Cohen S; Black S; Sampalis J; Colizza D; de Takacsy F; Schecter R;
    Curr Med Res Opin; 2013 Aug; 29(8):989-1000. PubMed ID: 23647369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rivastigmine as treatment for patients with mild to moderately severe Alzheimer disease under normal clinical practice conditions. The ENTERPRISE study].
    Cruz Jentoft AJ; Hernández B
    Neurologia; 2014; 29(1):1-10. PubMed ID: 23582372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers.
    Riepe M; Weinman J; Osae-Larbi J; Mulick Cassidy A; Knox S; Chaves R; Müller B
    Dement Geriatr Cogn Disord; 2015; 40(1-2):107-19. PubMed ID: 26066776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
    Cummings JL; Ferris SH; Farlow MR; Olin JT; Meng X
    Dement Geriatr Cogn Disord; 2010; 29(5):406-12. PubMed ID: 20502014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rivastigmine solution prescribing habits in patients with Alzheimer-type dementia in Spain (RIVASOL study)].
    González-Gutiérrez JL; Gobartt AL;
    Rev Neurol; 2007 Jun 16-30; 44(12):705-10. PubMed ID: 17583861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
    Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
    Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
    Borah B; Sacco P; Zarotsky V
    Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
    Pregelj P
    Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
    Winblad B; Kawata AK; Beusterien KM; Thomas SK; Wimo A; Lane R; Fillit H; Blesa R
    Int J Geriatr Psychiatry; 2007 May; 22(5):485-91. PubMed ID: 17407176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
    Muhlack S; Przuntek H; Müller T
    Pharmacopsychiatry; 2006 Jan; 39(1):16-9. PubMed ID: 16453249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease.
    Lee JH; Sevigny J
    Alzheimer Dis Assoc Disord; 2011; 25(1):58-62. PubMed ID: 20975519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
    Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
    Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions.
    Adler G; Mueller B; Articus K
    Int J Clin Pract; 2014 Apr; 68(4):465-70. PubMed ID: 24588972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.